Research chemical comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-04-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Marketed for research use in some regions. |
| Human clinical data | Limited or absent | Most evidence is from cell and animal studies. |
| Primary proposed pathway | HGF/c-Met signaling | Angiotensin IV-related activity also reported. |
| Common study models | Rodent neurons and behavioral tasks | Results may not translate directly to humans. |
| Key uncertainty | Bioavailability and brain exposure | Questions remain about absorption and target engagement. |
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
== Geography == Rhodesia is equivalent in territory to modern Zimbabwe. It was a landlocked country in southern Africa, lying between latitudes 15° and 23°S, and longitudes 25° and 34°E. It was bordered by South Africa to the south, the Bechuanaland Protectorate (later Botswana) to the west and southwest, Zambia to the northwest, and Mozambique to the east and northeast. Its northwest corner was roughly 150 metres (500 feet) from South West Africa (present-day Namibia), South Africa, nearly forming a four-nation quadripoint. Most of the country was elevated, consisting of a central plateau (high veld) stretching from the southwest northwards with altitudes between 1,000 and 1,600 m (3,300 and 5,200 ft). The country's extreme east was mountainous, this area being known as the Eastern Highlands, with Mount Inyangani as the highest point at 2,592 m (8,504 ft).
Adiponectin (also referred to as GBP-28, apM1, AdipoQ and Acrp30) is a protein hormone and adipokine, which is involved in regulating glucose levels and fatty acid breakdown. In humans, it is encoded by the ADIPOQ gene and is produced primarily in adipose tissue, but also in muscle and even in the brain.
Yohimbine selectively blocks the pre-synaptic α2-adrenergic receptors. Blockade of post-synaptic α2-adrenergic receptors causes only minor corpus cavernosum smooth muscle relaxation, due to the fact that the majority of adrenoceptors in the corpus cavernosum are of the α1 type. Blockade of pre-synaptic α2-adrenergic receptors facilitates the release of several neurotransmitters in the central and peripheral nervous system—thus in the corpus cavernosum—such as nitric oxide and norepinephrine. Whereas nitric oxide released in the corpus cavernosum is the major vasodilator contributing to the erectile process, norepinephrine is the major vasoconstrictor through stimulation of α1-adrenergic receptors on the corpus cavernosum smooth muscle. Under physiologic conditions, however, nitric oxide attenuates norepinephrine vasoconstriction. Yohimbine binds to the a2 adrenergic receptor at a ratio of 40:1 and is the only a2 adrenergic receptor antagonist with no imidazoline receptor activity.
=== Health === On September 1, 2019, Hart was a passenger in a 1970 Plymouth Barracuda that went off Mulholland Highway and rolled down an embankment near Calabasas, California. He and the driver reportedly suffered "major back injuries". Hart was released from a hospital 10 days later, and continued recovery at a rehabilitation facility. On August 23, 2023, Hart ran a 40-yard race with former National Football League running back Stevan Ridley, and tore his lower abductors on his abdomen. He required a wheelchair as part of his recovery and said afterward he is the "dumbest man alive" and "the age 40 is real", recommending no one attempt to race like he did.
Sources: en.wikipedia.org
=== Obesity and pseudoacanthosis nigricans (Type III) === In young people, acanthosis nigricans is a visible marker of insulin resistance. Elevated insulin stimulates epidermal proliferation. Insulin resistance syndromes may be classified as type A (HAIR-AN) or type B. Most cases are obesity-associated and otherwise idiopathic. This pattern is more common in darker-skinned individuals and is sometimes termed pseudoacanthosis nigricans. Facial involvement may appear as a horizontal forehead band or as periorbital or perioral hyperpigmentation.
The partial synthesis in the 1930s of abundant, potent testosterone esters permitted the characterization of the hormone's effects, so that Kochakian and Murlin (1936) were able to show that testosterone raised nitrogen retention (a mechanism central to anabolism) in the dog, after which Allan Kenyon's group was able to demonstrate both anabolic and androgenic effects of testosterone propionate in eunuchoidal men, boys, and women. The period of the early 1930s to the 1950s has been called "The Golden Age of Steroid Chemistry", and work during this period progressed quickly. Like other androsteroids, testosterone is manufactured industrially from microbial fermentation of plant cholesterol (e.g., from soybean oil). In the early 2000s, the steroid market weighed around one million tonnes and was worth $10 billion, making it the 2nd largest biopharmaceutical market behind antibiotics.
== Contraindications == Diclofenac is contraindicated for pregnant women; for people with active stomach or duodenal ulceration or gastrointestinal bleeding; and for people undergoing coronary artery bypass surgery.
Music hall historian Harold Scott wrote that: "..he sang at his piano perched upon a music stool always on the point of collapse, made jokes, gave satirical opinions upon the events of the day and commented unsparingly upon his own prodigious girth; the whole in the breathless manner and rather asthmatical voice, the management of which was the secret of his style." He made several recordings for Odeon Records, including "Limerickitis", and "Suffragettes' Anthem" (not to be confused with "The March of the Women"), in 1910, in which he was "careful to navigate that narrow line between being offensive and being uncontroversial." On the record, he introduces the song by saying that "the remarks [in the song] do not apply to those earnest ladies who are really earnest in their works, but rather the mountebank militants whose extraordinary antics seem to be alienating the sympathies of most right minded people, I refer to the Suffragettes...". The song itself is a parody of Gilbert and Sullivan's "Three Little Maids Are We" and Vesta Victoria's hit "Waiting at the Church": "There was I waiting in the cold, waiting in the cold, chained up in the cold...". In July 1912, Gammon was considered sufficiently respectable to be the opening act (other than a pair of acrobats, Pipifax and Panlo) at the first ever Royal Command Performance for music hall artists, held at the Palace Theatre in front of King George V, Queen Mary and Edward, Prince of Wales. He was a Freemason.
The two-star award was restored a year later in the 2009 Michelin Guide, as had been predicted by a number of Bosi's fellow chefs including Tom Aikens, Antonin Bonnet and Richard Corrigan. Sat Bains went a step further and said "I would love to see Claude Bosi regain his second star at Hibiscus and win his third in time. He's probably the best chef I know." The restaurant closed permanently in 2016, two days prior to the announcement of the 2017 Michelin Guide for UK and Ireland.
Sources: en.wikipedia.org
=== EC 2.7.7: Nucleotidyltransferases === EC 2.7.7.1: nicotinamide-nucleotide adenylyltransferase EC 2.7.7.2: FAD synthase EC 2.7.7.3: pantetheine-phosphate adenylyltransferase EC 2.7.7.4: sulfate adenylyltransferase EC 2.7.7.5: sulfate adenylyltransferase (ADP) EC 2.7.7.6: DNA-directed RNA polymerase EC 2.7.7.7: DNA-directed DNA polymerase EC 2.7.7.8: polyribonucleotide nucleotidyltransferase EC 2.7.7.9: UTP—glucose-1-phosphate uridylyltransferase EC 2.7.7.10: UTP—hexose-1-phosphate uridylyltransferase EC 2.7.7.11: UTP—xylose-1-phosphate uridylyltransferase EC 2.7.7.12: UDP-glucose—hexose-1-phosphate uridylyltransferase EC 2.7.7.13: mannose-1-phosphate guanylyltransferase EC 2.7.7.14: ethanolamine-phosphate cytidylyltransferase EC 2.7.7.15: choline-phosphate cytidylyltransferase EC 2.7.7.16: Now EC 4.6.1.18, pancreatic ribonuclease EC 2.7.7.17: Now EC 4.6.1.19, ribonuclease T2 EC 2.7.7.18: nicotinate-nucleotide adenylyltransferase EC 2.7.7.19: polynucleotide adenylyltransferase EC 2.7.7.20: deleted (identical with EC 2.7.7.72, CCA tRNA nucleotidyltransferase EC 2.7.7.21: Now EC 2.7.7.72, CCA tRNA nucleotidyltransferase EC 2.7.7.22: mannose-1-phosphate guanylyltransferase (GDP) EC 2.7.7.23: UDP-N-acetylglucosamine diphosphorylase EC 2.7.7.24: glucose-1-phosphate thymidylyltransferase EC 2.7.7.25: Now EC 2.7.7.72, CCA tRNA nucleotidyltransferase EC 2.7.7.26: Now EC 4.6.1.24, ribonuclease T1 EC 2.7.7.27: glucose-1-phosphate adenylyltransferase EC 2.7.7.28: nucleoside-triphosphate-hexose-1-phosphate nucleotidyltransferase EC 2.7.7.29: identical to EC 2.7.7.28, nucleoside-triphosphate-hexose-1-phosphate nucleotidyltransferase EC 2.7.7.30: fucose-1-phosphate guanylyltransferase EC 2.7.7.31: DNA nucleotidylexotransferase EC 2.7.7.32: galactose-1-phosphate thymidylyltransferase EC 2.7.7.33: glucose-1-phosphate cytidylyltransferase EC 2.7.7.34: glucose-1-phosphate guanylyltransferase EC 2.7.7.35: ribose-5-phosphate adenylyltransferase EC 2.7.7.36: aldose-1-phosphate adenylyltransferase EC 2.7.7.37: aldose-1-phosphate nucleotidyltransferase EC 2.7.7.38: 3-deoxy-manno-octulosonate cytidylyltransferase EC 2.7.7.39: glycerol-3-phosphate cytidylyltransferase EC 2.7.7.40: D-ribitol-5-phosphate cytidylyltransferase EC 2.7.7.41: phosphatidate cytidylyltransferase EC 2.7.7.42: [glutamine synthetase] adenylyltransferase EC 2.7.7.43: N-acylneuraminate cytidylyltransferase EC 2.7.7.44: glucuronate-1-phosphate uridylyltransferase EC 2.7.7.45: guanosine-triphosphate guanylyltransferase EC 2.7.7.46: gentamicin 2′′-nucleotidyltransferase EC 2.7.7.47: streptomycin 3′′-adenylyltransferase EC 2.7.7.48: RNA-directed RNA polymerase EC 2.7.7.49: RNA-directed DNA polymerase EC 2.7.7.50: mRNA guanylyltransferase EC 2.7.7.51: adenylylsulfate—ammonia adenylyltransferase EC 2.7.7.52: RNA uridylyltransferase EC 2.7.7.53: ATP adenylyltransferase EC 2.7.7.54: The activity is part of EC 6.3.2.40, cyclopeptine synthase EC 2.7.7.55: The activity is part of EC 6.3.2.40, cyclopeptine synthase EC 2.7.7.56: tRNA nucleotidyltransferase EC 2.7.7.57: N-methylphosphoethanolamine cytidylyltransferase EC 2.7.7.58: Now included in EC 6.2.1.71, 2,3-dihydroxybenzoate[aryl-carrier protein] ligase EC 2.7.7.59: [protein-PII] uridylyltransferase EC 2.7.7.60: 2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase EC 2.7.7.61: citrate lyase holo-[acyl-carrier protein] synthase EC 2.7.7.62: adenosylcobinamide-phosphate guanylyltransferase EC 2.7.7.63: Now EC 6.3.1.20, lipoate—protein ligase EC 2.7.7.64: UTP-monosaccharide-1-phosphate uridylyltransferase EC 2.7.7.65: diguanylate cyclase EC 2.7.7.66: malonate decarboxylase holo-[acyl-carrier protein] synthase EC 2.7.7.67: CDP-2,3-bis-(O-geranylgeranyl)-sn-glycerol synthase EC 2.7.7.68: 2-phospho-L-lactate guanylyltransferase EC 2.7.7.69: GDP-L-galactose/GDP-D-glucose: hexose 1-phosphate guanylyltransferase EC 2.7.7.70: D-glycero-β-D-manno-heptose 1-phosphate adenylyltransferase EC 2.7.7.71: D-glycero-α-D-manno-heptose 1-phosphate guanylyltransferase EC 2.7.7.72: CCA tRNA nucleotidyltransferase EC 2.7.7.73: sulfur carrier protein ThiS adenylyltransferase EC 2.7.7.74: 1L-myo-inositol 1-phosphate cytidylyltransferase EC 2.7.7.75: molybdopterin adenylyltransferase EC 2.7.7.76: molybdenum cofactor cytidylyltransferase EC 2.7.7.77: molybdenum cofactor guanylyltransferase EC 2.7.7.78: GDP-D-glucose phosphorylase EC 2.7.7.79: tRNAHis guanylyltransferase EC 2.7.7.80: molybdopterin-synthase adenylyltransferase EC 2.7.7.81: pseudaminic acid cytidylyltransferase EC 2.7.7.82: CMP-N,N′-diacetyllegionaminic acid synthase EC 2.7.7.83: UDP-N-acetylgalactosamine diphosphorylase EC 2.7.7.84: diadenylate cyclase EC 2.7.7.85: 2′-5′ oligoadenylate synthase EC 2.7.7.86: cyclic GMP-AMP synthase EC 2.7.7.87: L-threonylcarbamoyladenylate synthase EC 2.7.7.88: GDP polyribonucleotidyltransferase EC 2.7.7.89: [glutamine synthetase]-adenylyl-L-tyrosine phosphorylase EC 2.7.7.90: 8-amino-3,8-dideoxy-''manno''-octulosonate cytidylyltransferase EC 2.7.7.91: valienol-1-phosphate guanylyltransferase EC 2.7.7.92: 3-deoxy-D-glycero-D-galacto-nonulopyranosonate cytidylyltransferase EC 2.7.7.93: phosphonoformate cytidylyltransferase EC 2.7.7.94: Now EC 6.2.1.51, 4-hydroxyphenylalkanoate adenylyltransferase FadD29 EC 2.7.7.95: Now EC 6.2.1.49, long-chain fatty acid adenylyltransferase FadD28 EC 2.7.7.96: ADP-D-ribose pyrophosphorylase EC 2.7.7.97: 3-hydroxy-4-methylanthranilate adenylyltransferase EC 2.7.7.98: Now EC 6.2.1.50, 4-hydroxybenzoate adenylyltransferase FadD22 EC 2.7.7.99: N-acetyl-α-D-muramate 1-phosphate uridylyltransferase EC 2.7.7.100: SAMP-activating enzyme EC 2.7.7.101: DNA primase DnaG EC 2.7.7.102: DNA primase AEP EC 2.7.7.103: L-glutamine-phosphate cytidylyltransferase EC 2.7.7.104: 2-hydroxyethylphosphonate cytidylyltransferase EC 2.7.7.105: phospho''enol''pyruvate guanylyltransferase EC 2.7.7.106: 3-phospho-D-glycerate guanylyltransferase
Therefore, techniques utilising relaxation measurements of carbon-13 and deuterium have recently been developed, which enables systematic studies of motions of the amino acid side-chains in proteins. A challenging and special case of study regarding dynamics and flexibility of peptides and full-length proteins is represented by disordered structures. Nowadays, it is an accepted concept that proteins can exhibit a more flexible behaviour known as disorder or lack of structure; however, it is possible to describe an ensemble of structures instead of a static picture representing a fully functional state of the protein. Many advances are represented in this field in particular in terms of new pulse sequences, technological improvement, and rigorous training of researchers in the field.
Polyvinylidene fluoride or polyvinylidene difluoride (PVDF) is a highly non-reactive thermoplastic fluoropolymer produced by the polymerization of vinylidene difluoride. Its chemical formula is (C2H2F2)n. PVDF is a specialty plastic used in applications requiring the highest purity, as well as resistance to solvents, acids and hydrocarbons. PVDF has a lower density of 1.78 g/cm3 in comparison to other fluoropolymers, like polytetrafluoroethylene. It is available in the form of piping products, sheet, tubing, films, plate and an insulator for premium wire. It can be injected, molded or welded and is commonly used in the chemical, semiconductor, medical and defense industries, as well as in lithium-ion batteries. It is also available as a cross-linked closed-cell foam, used increasingly in aviation and aerospace applications, and as an exotic 3D printer filament. It can also be used in repeated contact with food products, as it is FDA-compliant and non-toxic below its degradation temperature. As a fine powder grade, it is an ingredient in high-end paints for metals. These PVDF paints have extremely good gloss and color retention. They are in use on many prominent buildings around the world, such as the Petronas Towers in Malaysia and Taipei 101 in Taiwan, as well as on commercial and residential metal roofing. In biotechnology, PVDF membranes are used to immobilize proteins for a western blot. PVDF is also used as a binder component for the carbon electrode in supercapacitors and for other electrochemical applications.
Head, Children and Young People's Service, The Rathbone Society. For services to Young People. Penelope Anne Kirby. For services to Mountain Rescue in the Lake District. Henry James Kissock. Information and Communication Technology Service Delivery Manager, Police Service of Northern Ireland. For services to the community in Northern Ireland. Melissa Kose. Emerging Talent Manager, British Airways. For services to Early Careers in Aviation. Mostaque Ahmed Koyes. Director, Community Interest Luton. For services to the community in Luton, Bedfordshire. Anna Ruth Ella Lapwood. Organist. For services to Music. Harriet Hannah Laurie. Founder, TheHorseCourse. For services to Disadvantaged People in Dorset. Jayne Anne Law. Lately Head of Honours and the Kings Award for Voluntary Service, Department for Culture, Media and Sport. For Public Service. Dr. Fenella Kate Leach (Fenella Wrigley). Chief Medical Officer and Deputy Chief Executive, London Ambulance Service NHS Trust. For services to the NHS. Helen Margaret Leadbitter. For services to Young Carers. Aryeh Leaman. For services to Young People and to the community in Hendon, London Borough of Barnet. Jeremy James Lee. Chef. For services to the Food Industry. David Levy. Senior Community Outreach Adviser, Ukraine Humanitarian Taskforce, Department for Levelling Up, Housing and Communities. For services to Refugee Resettlement. Andrew Colin MacDuff Liddell. Lately Charity Lawyer, Pitlochry. For services to Theatre and the Arts in Scotland. Fiona Ann Lindop.
=== Labor concerns === Employees have criticized the company's productivity goals, in which they say volume and speed of work done is prioritized over quality. Labs face staffing shortages and employees say they are overworked. Labcorp has been criticized for its process of having all employees terminated upon hospital laboratory management acquisitions, and making them reapply with LabCorp, thereby losing accrued employee benefits, including employee eligibility for Public Service Loan Forgiveness (PSLF) in the case of non-profit hospitals. In 2024, Labcorp stated that its goal is to "operate the company in a non-union environment." After Labcorp became the manager of laboratories of Legacy Health, outsourced laboratory personnel unionized with the Oregon Federation of Nurses and Health Professionals.
Sources: en.wikipedia.org
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.
Preclinical research has focused on synaptic growth, cognitive performance in animals, and HGF/c-Met signaling. These are experimental findings, not established treatments.
Legality varies by country and intended use. It is commonly sold as a research chemical, and sales for human consumption may be restricted. Local regulations should be checked.
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.